What is the current market valuation of the myasthenia gravis market in Germany as of 2024?

The overall market valuation was $83.71 Million in 2024. Read More

What is the projected market valuation for the myasthenia gravis market in Germany by 2035?

The projected valuation for 2035 is $194.04 Million. Read More

What is the expected CAGR for the myasthenia gravis market in Germany during the forecast period 2025 - 2035?

The expected CAGR for the market during this period is 7.94%. Read More

Which companies are the key players in the myasthenia gravis market in Germany?

Key players include Roche (CH), Bristol-Myers Squibb (US), Novartis (CH), Sanofi (FR), Pfizer (US), Merck & Co. (US), AstraZeneca (GB), Eisai (JP), and Amgen (US). Read More

What is the market size for Immunosuppressants in the myasthenia gravis market in Germany?

The market size for Immunosuppressants ranged from $25.0 Million to $60.0 Million. Read More

What are the primary routes of administration for treatments in the myasthenia gravis market in Germany?

Primary routes of administration include Oral, Intravenous, and Subcutaneous. Read More

What is the market size for homecare settings in the myasthenia gravis market in Germany?

The market size for homecare settings ranged from $28.71 Million to $64.04 Million. Read More

Germany Myasthenia Gravis Market

Q: What are the main disease types contributing to the myasthenia gravis market in Germany?

The main disease types include Acetylcholine Receptor Antibody Positive Myasthenia Gravis, Muscle-Specific Kinase Antibody Positive Myasthenia Gravis, and Seronegative Myasthenia Gravis. Read More

Q: What is the market size for Acetylcholine Receptor Antibody Positive Myasthenia Gravis in Germany?

The market size for Acetylcholine Receptor Antibody Positive Myasthenia Gravis ranged from $30.0 Million to $70.0 Million. Read More

Q: What treatment types are prevalent in the myasthenia gravis market in Germany?

Prevalent treatment types include Anticholinesterase Agents, Immunosuppressants, Intravenous Immunoglobulin, Plasmapheresis, and Thymectomy. Read More

ID: MRFR/HC/47604-HCR

200 Pages

Rahul Gotadki

Last Updated: April 06, 2026

Germany Myasthenia Gravis Market Research Report By Disease Type (Acetylcholine Receptor Antibody Positive Myasthenia Gravis, Muscle-Specific Kinase Antibody Positive Myasthenia Gravis, Seronegative Myasthenia Gravis), By Treatment Type (Anticholinesterase Agents, Immunosuppressants, Intravenous Immunoglobulin, Plasmapheresis, Thymectomy), By Route of Administration (Oral, Intravenous, Subcutaneous) and By End User (Hospitals, Specialty Clinics, Homecare Settings) - Growth & Industry Forecast 2025 To 2035

Germany Myasthenia Gravis Market Infographic

Summary Table of Contents Segmentation Download PDF

Certified Researchers

Customize Report

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Pharmaceutical, BY Disease Type (USD Million)
  1. 4.1.1 Acetylcholine Receptor Antibody Positive Myasthenia Gravis
  2. 4.1.2 Muscle-Specific Kinase Antibody Positive Myasthenia Gravis
  3. 4.1.3 Seronegative Myasthenia Gravis
2. 4.2 Pharmaceutical, BY Treatment Type (USD Million)
  1. 4.2.1 Anticholinesterase Agents
  2. 4.2.2 Immunosuppressants
  3. 4.2.3 Intravenous Immunoglobulin
  4. 4.2.4 Plasmapheresis
  5. 4.2.5 Thymectomy
3. 4.3 Pharmaceutical, BY Route of Administration (USD Million)
  1. 4.3.1 Oral
  2. 4.3.2 Intravenous
  3. 4.3.3 Subcutaneous
4. 4.4 Pharmaceutical, BY End User (USD Million)
  1. 4.4.1 Hospitals
  2. 4.4.2 Specialty Clinics
  3. 4.4.3 Homecare Settings
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Pharmaceutical
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Pharmaceutical
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Roche (CH)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Bristol-Myers Squibb (US)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Novartis (CH)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Sanofi (FR)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Pfizer (US)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Merck & Co. (US)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 AstraZeneca (GB)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Eisai (JP)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
  9. 5.2.9 Amgen (US)
    1. 5.2.9.1 Financial Overview
    2. 5.2.9.2 Products Offered
    3. 5.2.9.3 Key Developments
    4. 5.2.9.4 SWOT Analysis
    5. 5.2.9.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 GERMANY MARKET ANALYSIS BY DISEASE TYPE
3. 6.3 GERMANY MARKET ANALYSIS BY TREATMENT TYPE
4. 6.4 GERMANY MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
5. 6.5 GERMANY MARKET ANALYSIS BY END USER
6. 6.6 KEY BUYING CRITERIA OF PHARMACEUTICAL
7. 6.7 RESEARCH PROCESS OF MRFR
8. 6.8 DRO ANALYSIS OF PHARMACEUTICAL
9. 6.9 DRIVERS IMPACT ANALYSIS: PHARMACEUTICAL
10. 6.10 RESTRAINTS IMPACT ANALYSIS: PHARMACEUTICAL
11. 6.11 SUPPLY / VALUE CHAIN: PHARMACEUTICAL
12. 6.12 PHARMACEUTICAL, BY DISEASE TYPE, 2024 (% SHARE)
13. 6.13 PHARMACEUTICAL, BY DISEASE TYPE, 2024 TO 2035 (USD Million)
14. 6.14 PHARMACEUTICAL, BY TREATMENT TYPE, 2024 (% SHARE)
15. 6.15 PHARMACEUTICAL, BY TREATMENT TYPE, 2024 TO 2035 (USD Million)
16. 6.16 PHARMACEUTICAL, BY ROUTE OF ADMINISTRATION, 2024 (% SHARE)
17. 6.17 PHARMACEUTICAL, BY ROUTE OF ADMINISTRATION, 2024 TO 2035 (USD Million)
18. 6.18 PHARMACEUTICAL, BY END USER, 2024 (% SHARE)
19. 6.19 PHARMACEUTICAL, BY END USER, 2024 TO 2035 (USD Million)
20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 Germany MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY DISEASE TYPE, 2025-2035 (USD Million)
  2. 7.2.2 BY TREATMENT TYPE, 2025-2035 (USD Million)
  3. 7.2.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million)
  4. 7.2.4 BY END USER, 2025-2035 (USD Million)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

Germany Pharmaceutical Market Segmentation

Pharmaceutical By Disease Type (USD Million, 2025-2035)

Acetylcholine Receptor Antibody Positive Myasthenia Gravis
Muscle-Specific Kinase Antibody Positive Myasthenia Gravis
Seronegative Myasthenia Gravis

Pharmaceutical By Treatment Type (USD Million, 2025-2035)

Anticholinesterase Agents
Immunosuppressants
Intravenous Immunoglobulin
Plasmapheresis
Thymectomy

Pharmaceutical By Route of Administration (USD Million, 2025-2035)

Oral
Intravenous
Subcutaneous

Pharmaceutical By End User (USD Million, 2025-2035)

Hospitals
Specialty Clinics
Homecare Settings

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”